Relay Therapeutics, Inc. Net Income (Loss) Available to Common Stockholders, Basic
Relay Therapeutics, Inc. (RLAY) reported Net Income (Loss) Available to Common Stockholders, Basic of -$363.87 million for the 12-month period ending 2021-12-31, per its 10-K filed 2022-02-24.
Discontinued › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2022-02-24
- Relay Therapeutics, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2021-12-31 was -$67.46M, a 291.22% decline year-over-year.
- Relay Therapeutics, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2021-09-30 was -$60.83M.
- Relay Therapeutics, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2020-12-31 was $35.28M.
- Relay Therapeutics, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2020-09-30 was -$213.87M.
- Relay Therapeutics, Inc. net income (loss) available to common stockholders, basic for fiscal 2021 was -$363.87M.
- Relay Therapeutics, Inc. net income (loss) available to common stockholders, basic for fiscal 2020 was -$230.20M.
- Relay Therapeutics, Inc. net income (loss) available to common stockholders, basic for fiscal 2019 was -$75.31M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month |
|---|---|---|---|---|
| 2021-12-31 | -$67.46M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | -$128.29M derived: sum of 2 quarters · filed 2022-02-24 | -$363.87M 10-K · filed 2022-02-24 | |
| 2021-09-30 | -$60.83M 10-Q · filed 2021-11-10 | -$296.42M 10-Q · filed 2021-11-10 | ||
| 2020-12-31 | $35.28M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | -$178.59M derived: sum of 2 quarters · filed 2022-02-24 | -$230.20M 10-K · filed 2022-02-24 | |
| 2020-09-30 | -$213.87M 10-Q · filed 2021-11-10 | -$265.48M 10-Q · filed 2021-11-10 | ||
| 2019-12-31 | -$23.91M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | -$43.59M derived: sum of 2 quarters · filed 2022-02-24 | -$75.31M 10-K · filed 2022-02-24 | |
| 2019-09-30 | -$19.67M 10-Q · filed 2020-11-12 | -$51.39M 10-Q · filed 2020-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |